These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34365130)

  • 21. Will fluoroquinolones ever be recommended for common infections in children?
    Schaad UB
    Pediatr Infect Dis J; 2007 Oct; 26(10):865-7. PubMed ID: 17901790
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
    Parra-Ruiz J; Hernández-Quero J
    Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
    Bhawsar S; Joshi S; Deshpande P; Yeole R; Bhagwat S; Patel M
    Bioorg Med Chem Lett; 2022 May; 63():128665. PubMed ID: 35276361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and Evaluation of Thiazolidine Amide and N-Thiazolyl Amide Fluoroquinolone Derivatives.
    Garza I; Wallace MJ; Fernando D; Singh A; Lee RE; Gerding JS; Franklin C; Yendapally R
    Arch Pharm (Weinheim); 2017 Jun; 350(6):. PubMed ID: 28429393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoroquinolone-Resistant Mycoplasma genitalium, Southwestern France.
    Le Roy C; Hénin N; Pereyre S; Bébéar C
    Emerg Infect Dis; 2016 Sep; 22(9):1677-9. PubMed ID: 27533360
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecular mechanisms of fluoroquinolone resistance.
    Chen FJ; Lo HJ
    J Microbiol Immunol Infect; 2003 Mar; 36(1):1-9. PubMed ID: 12741725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone.
    Fujimaki K; Noumi T; Saikawa I; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1988 Jun; 32(6):827-33. PubMed ID: 2843082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
    Lapointe G; Skepper CK; Holder LM; Armstrong D; Bellamacina C; Blais J; Bussiere D; Bian J; Cepura C; Chan H; Dean CR; De Pascale G; Dhumale B; Fisher LM; Fulsunder M; Kantariya B; Kim J; King S; Kossy L; Kulkarni U; Lakshman J; Leeds JA; Ling X; Lvov A; Ma S; Malekar S; McKenney D; Mergo W; Metzger L; Mhaske K; Moser HE; Mostafavi M; Namballa S; Noeske J; Osborne C; Patel A; Patel D; Patel T; Piechon P; Polyakov V; Prajapati K; Prosen KR; Reck F; Richie DL; Sanderson MR; Satasia S; Savani B; Selvarajah J; Sethuraman V; Shu W; Tashiro K; Thompson KV; Vaarla K; Vala L; Veselkov DA; Vo J; Vora B; Wagner T; Wedel L; Williams SL; Yendluri S; Yue Q; Yifru A; Zhang Y; Rivkin A
    J Med Chem; 2021 May; 64(9):6329-6357. PubMed ID: 33929852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, molecular docking study, and antibacterial evaluation of some new fluoroquinolone analogues bearing a quinazolinone moiety.
    Norouzbahari M; Salarinejad S; Güran M; Şanlıtürk G; Emamgholipour Z; Bijanzadeh HR; Toolabi M; Foroumadi A
    Daru; 2020 Dec; 28(2):661-672. PubMed ID: 33030668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interplay in the selection of fluoroquinolone resistance and bacterial fitness.
    Marcusson LL; Frimodt-Møller N; Hughes D
    PLoS Pathog; 2009 Aug; 5(8):e1000541. PubMed ID: 19662169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity and action mode of Cu(I) and Cu(II) complexes with phosphines derived from fluoroquinolone against clinical and multidrug-resistant bacterial strains.
    Guz-Regner K; Komarnicka UK; Futoma-Kołoch B; Wernecki M; Cal M; Kozieł S; Ziółkowska A; Bugla-Płoskońska G
    J Inorg Biochem; 2020 Sep; 210():111124. PubMed ID: 32534287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lascufloxacin hydrochloride to treat bacterial infection.
    Thakare R; Singh S; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Jun; 56(6):365-376. PubMed ID: 32525135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel 3-arylfuran-2(5H)-one-fluoroquinolone hybrid: design, synthesis and evaluation as antibacterial agent.
    Wang XD; Wei W; Wang PF; Tang YT; Deng RC; Li B; Zhou SS; Zhang JW; Zhang L; Xiao ZP; Ouyang H; Zhu HL
    Bioorg Med Chem; 2014 Jul; 22(14):3620-8. PubMed ID: 24882676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success.
    Redgrave LS; Sutton SB; Webber MA; Piddock LJ
    Trends Microbiol; 2014 Aug; 22(8):438-45. PubMed ID: 24842194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid evolution of fluoroquinolone-resistant Escherichia coli in Nigeria is temporally associated with fluoroquinolone use.
    Lamikanra A; Crowe JL; Lijek RS; Odetoyin BW; Wain J; Aboderin AO; Okeke IN
    BMC Infect Dis; 2011 Nov; 11():312. PubMed ID: 22060770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.
    de Lastours V; Chau F; Roy C; Larroque B; Fantin B
    J Antimicrob Chemother; 2014 Dec; 69(12):3393-400. PubMed ID: 25063781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
    O'Brien TP
    Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards anticancer fluoroquinolones: A review article.
    Abdel-Aal MAA; Abdel-Aziz SA; Shaykoon MSA; Abuo-Rahma GEA
    Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800376. PubMed ID: 31215674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.